𝔖 Bobbio Scriptorium
✦   LIBER   ✦

α-Interferon in hematological malignancies

✍ Scribed by Frank J. Giles; Howard Ozer

Book ID
113404979
Publisher
Elsevier Science
Year
1992
Tongue
English
Weight
317 KB
Volume
2
Category
Article
ISSN
0960-9822

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

α-interferon in hematological malignanci
α-interferon in hematological malignancies
✍ Frank J. Giles; Howard Ozer 📂 Article 📅 1991 🏛 Elsevier Science 🌐 English ⚖ 381 KB

Recent studies have generated data demonstrating significant clinical activity of a-interferon therapy in each of six hematological malignancies, chronic myeloid leukaemia, essential thrombocythemia, polycythemia rubra vera, non-Hodgkin's lymphomas, multiple myelomatosis and hairy cell leukaemia.

Pulmonary side effects of interferon-α t
Pulmonary side effects of interferon-α therapy in patients with hematological malignancies
✍ Patrik Anderson; Martin Höglund; Stig Rödjer 📂 Article 📅 2003 🏛 John Wiley and Sons 🌐 English ⚖ 56 KB 👁 1 views

## Abstract Several side effects of interferon‐α‐2b (IFN‐α) therapy have been described. Pulmonary side effects have seldom been reported. The four patients we describe all developed respiratory disorders while being treated with IFN‐α for hematological malignancies. We point out the similarities a

A phase I trial of α-interferon in combi
A phase I trial of α-interferon in combination with pentostatin in hematologic malignancies
✍ Bernard, Stephen ;Gill, Parkash ;Rosen, Peter ;Gavigan, Molly ;Steagall, Ann ;El 📂 Article 📅 1991 🏛 John Wiley and Sons 🌐 English ⚖ 721 KB

Pentostatin, a novel inhibitor of adenosine deaminase, has shown activity in various lymphoid malignancies of both the T and B cell lineage. This agent has unique side effects and in general myelosuppression has been mild. Interferon has both antiviral and antineoplastic properties. This agent has s